Search
Hydrastine
go.drugbank.com/drugs/DB19354ExperimentalCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 SubstratesSetileuton
go.drugbank.com/drugs/DB19550InvestigationalSetileuton is a small molecule drug. The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory. Setileuton is under investigation in clinical trial NCT00404313 (The Effec...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMifentidine
go.drugbank.com/drugs/DB19721ExperimentalMifentidine is a small molecule drug. The usage of the INN stem '-tidine' in the name indicates that Mifentidine is a histamine- H2-receptor antagonist, cimetidine derivative. Mifentidine has a monoisotopic molecular weight of 228.14 Da.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsLefetamine
go.drugbank.com/drugs/DB19944ExperimentalLefetamine is a small molecule drug. Lefetamine has a monoisotopic molecular weight of 225.15 Da.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTauromustine
go.drugbank.com/drugs/DB19978ExperimentalTauromustine is a small molecule drug. The usage of the INN stem '-mustine' in the name indicates that Tauromustine is a antineoplastic, alkylating agent, (β-chloroethyl) amine derivative. Tauromustine has a monoisotopic molecular weight...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNavamepent
go.drugbank.com/drugs/DB21096InvestigationalNavamepent is a small molecule drug. Navamepent is under investigation in clinical trial NCT02329743 (Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery). Navamepent has a monoisotopi...
Categories: P-glycoprotein inhibitorsFilapixant
go.drugbank.com/drugs/DB21467ExperimentalFilapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Filapixant is a purinoreceptor (P2X) antagonist. Filapixant has a monoisotopic molecular weight of 521.17 Da.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDaraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigationalDaraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bou...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAzamulin
go.drugbank.com/drugs/DB20304ExperimentalAzamulin is a small molecule drug. Azamulin has a monoisotopic molecular weight of 478.26 Da.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates